LEASE AGREEMENTLease Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • Massachusetts
THIS LEASE AGREEMENT (this “Lease”) is made this 2nd day of November, 2015, between ARE-MA REGION NO. 20, LLC, a Delaware limited liability company (“Landlord”), and DIMENSION THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
This COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is entered into as of June 18, 2014 (“Effective Date”) by and between Dimension Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 1 Main Street, 13th Floor, Cambridge, MA 02142 (“Dimension”), and Bayer HealthCare LLC, a limited liability company organized under the laws of the State of Delaware, with offices at 455 Mission Bay Blvd South, San Francisco, CA 94158 (“Bayer”). Dimension and Bayer are hereinafter referred to individually as a “Party” and collectively as the “Parties.”
OPTION AND LICENSE AGREEMENTOption and License Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
This OPTION AND LICENSE AGREEMENT (“Agreement”) is entered into as of March 10, 2015 (the “Execution Date”), with effectiveness as of February 18, 2014 (the “Effective Date”), by and between REGENXBIO Inc., a limited liability company organized under the laws of the State of Delaware, with offices at 1701 Pennsylvania Avenue, NW, Suite 900, Washington, DC 20006 (“Licensor”), and Dimension Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (“Licensee”). Licensor and Licensee are hereinafter referred to individually as a “Party” and collectively as the “Parties.”
INDENTURE OF LEASEIndenture of Lease • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • Massachusetts
Agreement entered into this 11thday of March, 2014 in consideration of the covenants and other benefits herein contained the receipt and sufficiency of said consideration being hereby acknowledged.
RESEARCH, COLLABORATION & LICENSE AGREEMENT DATED AS OF MAY 5, 2016 BY AND BETWEEN THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA AND DIMENSION THERAPEUTICS, INC.License Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • Pennsylvania
This Research, Collaboration & License Agreement (this “Agreement”) is dated as of May 5, 2016 (the “Effective Date”) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Dimension Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (“Licensee”). Penn and Licensee may be referred to herein as a “Party” or, collectively, as “Parties”.
LICENSE AGREEMENTLicense Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
This LICENSE AGREEMENT (“Agreement”) is entered into as of October 30, 2013 (“Effective Date”) by and between ReGenX Biosciences, LLC, a limited liability company organized under the laws of the State of Delaware, with offices at 750 17thStreet, NW, Suite 1100, Washington, DC 20006 (“Licensor”), and Dimension Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 1 Main Street, 13thFloor, Cambridge, MA 02142 (“Licensee”). Licensor and Licensee are hereinafter referred to individually as a “Party” and collectively as the “Parties.”
PERFORMANCE STOCK UNIT AGREEMENT (NEW EMPLOYEES)Performance Stock Unit Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This agreement (this “Agreement”) evidences an award (the “Award”) of performance stock units (the “Performance Stock Units”) granted by Ultragenyx Pharmaceutical Inc. (the “Company”) to the undersigned (the “Grantee”) pursuant to and subject to the terms of the Ultragenyx Pharmaceutical Inc. 2014 Incentive Plan (as amended from time to time, the “Plan”), which is incorporated herein by reference.
AMENDMENT NO. 2 TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This Amendment No. 2 to the Collaboration and License Agreement (“Amendment”) is made and entered into by and between Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185, Japan (“KHK”) and Ultragenyx Pharmaceutical Inc., a company organized and existing under the laws of the State of Delaware, with an address at 60 Leveroni Court, Novato, California 94949, USA (“UGNX”).
RIVERSIDE TECHNOLOGY CENTER SECOND LEASE AMENDMENT TO THE LEASE BETWEEN RIVERTECH ASSOCIATES II, LLC AND DIMENSION THERAPEUTICS, INC.Lease Between • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • Massachusetts
This Second Lease Amendment (the “Second Amendment”) entered into this 28th day of April, 2017 by and between Rivertech Associates II, LLC, a Massachusetts limited liability company with a principal address c/o The Abbey Group, 177 Huntington Avenue 24th Floor Boston, MA 02115 (herein the “Lessor”), and Dimension Therapeutics, Inc., with a business address at 840 Memorial Drive Cambridge, Massachusetts (herein the “Lessee”); with respect to a certain Lease dated March 11, 2014 (the “Original Lease”) for certain office and laboratory space in the building at 840 Memorial Drive Cambridge, Massachusetts, as amended by a certain First Lease Amendment dated October 22, 2014 (the “First Amendment”); collectively referred to herein as the “Existing Lease”).
ADDENDUM 1 TO LEASE DATED 12/17/2015 BY AND BETWEEN CONDIOTTI ENTERPRISES, INC AS LESSOR AND ULTRAGENYX PHARMACEUTICAL INC. AS LESSEEUltragenyx Pharmaceutical Inc. • February 21st, 2018 • Pharmaceutical preparations
AMENDMENT NO. 3 TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This Amendment No. 3 to the Collaboration and License Agreement (“Amendment”) is made and entered into by and between Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Otemachi, Chiyoda-ku, Tokyo, 100-0004, Japan (“KHK”) and Ultragenyx Pharmaceutical Inc., a company organized and existing under the laws of the State of Delaware, with an address at 60 Leveroni Court, Novato, California 94949, USA (“UGNX”).
Addendum 3 To The Lease Dated 12/17/15 By and Between Ultragenyx Pharmaceutical Inc. As Lessee and Condiotti Enterprises, Inc. As LessorUltragenyx Pharmaceutical Inc. • February 21st, 2018 • Pharmaceutical preparations
On or about December 17, 2015 the above Parties entered into a Lease and Addendum 1 (the “Lease”) for the entire Premises of 81 Digital Drive, Novato, California, which included approximately 25,100sf. On or about March 14, 2016 the Parties executed Addendum 2, which added approximately 4,388sf of first and second floor office at 77 Digital, the Term for which has been extended to December 31, 2020.
ASSET PURCHASE AGREEMENT BY AND BETWEEN NOVARTIS PHARMA AG, ULTRAGENYX PHARMACEUTICAL INC., AND ULTRAGENYX INTERNATIONAL UX003 LTD. December 14, 2017Asset Purchase Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • Delaware
This ASSET PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of December 14, 2017 (the “Effective Date”), by and between Novartis Pharma AG, a Switzerland corporation (“Buyer”), Ultragenyx Pharmaceutical Inc., a Delaware corporation (“U.S. Seller”), and Ultragenyx International UX003 Ltd., an exempted company incorporated in the Cayman Islands and a wholly-owned subsidiary of the U.S. Seller (the “Cayman Seller,” and together with the U.S. Seller, the “Sellers”). Buyer and Sellers may hereinafter be referred to individually as a “Party” and collectively as the “Parties.”
COMMERCIAL SUPPLY AND SERVICES AGREEMENT - DRUG SUBSTANCE -Supply and Services Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
WHEREAS, Rentschler is a company engaged in the field of pharmaceutical contract development, services and manufacturing and has the know-how, expertise, capability, experience and the infrastructure necessary to undertake certain commercial Services (as defined hereinafter); and
3rd AMENDMENT TO RESEARCH, COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This THIRD AMENDMENT (“Third Amendment”) is entered into as of October 30, 2017 (the “Third Amendment Effective Date”) by and between Dimension Therapeutics Inc., having its principal offices at 840 Memorial Drive, Cambridge, MA 02139 (“Licensee”), and The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at Penn Center for Innovation, 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104-6228 (“Penn”). Licensee and Penn are sometimes hereinafter referred to collectively as the “Parties” and individually as a “Party.”
Addendum 2 To The Lease Dated 12/17/15 By and Between Ultragenyx Pharmaceutical Inc. As Lessee and Condiotti Enterprises, Inc. As LessorUltragenyx Pharmaceutical Inc. • February 21st, 2018 • Pharmaceutical preparations
On or about December 17, 2015 the above Parties entered into a Lease and Addendum 1 (the “Lease”) for the entire Premises of 81 Digital Drive, Novato, California which included approximately 25,100sf. The Parties now wish to incorporate the following provisions into that Lease:
AMENDMENT NO. 4 TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This Amendment No. 4 to the Collaboration and License Agreement (this "Amendment") is made and entered into as of January 29, 2018 (“Effective Date”), by and between Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Ohtemachi, Chiyoda-ku, Tokyo, 100- 0004, Japan ("KHK") and Ultragenyx Pharmaceutical Inc., a company organized and existing under the laws of the State of Delaware, with an address at 60 Leveroni, Novato, California 94949, USA ("UGNX'').
SUPPLY AGREEMENTSupply Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
Whereas, Ultragenyx is a biotechnology company committed to bringing life-enhancing therapeutics for patients with rare and ultra-rare genetic diseases, also known as orphan diseases, to market;
COMMERCIAL SUPPLY AND SERVICES AGREEMENT - Drug Product-Supply and Services Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
WHEREAS, Rentschler has the know-how, expertise, capability, experience and the infrastructure necessary to manufacture the Drug Substance to a final Product ready for labelling subject to and in accordance with the terms hereof; and
